Loading institutional data...
Loading institutional data...
Strong institutional distribution: ownership decreased -3.60% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $90.5M 100.0% | $83.8M 100.0% | $68.7M 100.0% | $53.7M 100.0% | $48.4M 100.0% | $32.7M 100.0% | $32.6M 100.0% | $20.0M 100.0% |
| Cost of Revenue | $23.4M 25.8% | $21.8M 26.0% | $17.9M 26.1% | $13.8M 25.7% | $12.8M 26.4% | $11.5M 35.2% | $10.2M 31.2% | $7.7M 38.6% |
| Gross Profit | $67.1M 74.2% | $62.0M 74.0% | $50.8M 73.9% | $39.9M 74.3% | $35.6M 73.6% | $21.2M 64.8% | $22.4M 68.8% | $12.3M 61.4% |
| Research & Development | $19.5M 21.5% | $17.6M 21.0% | $18.1M 26.3% | $15.4M 28.7% | $13.1M 27.0% | $7.5M 22.8% | $6.0M 18.6% | $7.0M 34.9% |
| Selling, General & Admin | $101.3M 111.9% | $102.1M 121.9% | $94.6M 137.8% | $83.1M 154.9% | $69.9M 144.3% | $46.1M 140.8% | $34.2M 104.9% | $20.3M 101.7% |
| Total Operating Expenses | $120.8M 133.5% | $119.7M 142.9% | $112.7M 164.1% | $98.5M 183.6% | $82.9M 171.3% | $53.5M 163.5% | $40.3M 123.5% | $27.3M 136.7% |
| Operating Income | -$53.7M -59.3% | -$57.7M -68.9% | -$61.9M -90.2% | -$58.6M -109.3% | -$47.3M -97.7% | -$32.3M -98.8% | -$17.8M -54.7% | -$15.1M -75.2% |
| Interest Expense | $3.2M 3.5% | $3.5M 4.2% | $3.2M 4.7% | $1.1M 2.0% | $829K 1.7% | $3.2M 9.7% | $2.3M 7.1% | $2.5M 12.6% |
| Interest & Investment Income | $2.7M 2.9% | $5.1M 6.0% | $5.6M 8.1% | $1.5M 2.8% | $400K 0.8% | $213K 0.7% | $432K 1.3% | $21K 0.1% |
| Other Income (Expense), net | $790K 0.9% | $256K 0.3% | -$673K -1.0% | -$396K -0.7% | -$585K -1.2% | $3.3M 10.0% | -$617K -1.9% | -$916K -4.6% |
| Pretax Income | -$53.4M -59.0% | -$55.9M -66.7% | -$60.3M -87.8% | -$58.6M -109.1% | -$48.3M -99.8% | -$32.0M -97.8% | -$20.3M -62.4% | -$18.5M -92.3% |
| Income Tax Expense | $626K 0.7% | $500K 0.6% | $571K 0.8% | $353K 0.7% | $343K 0.7% | $213K 0.7% | $363K 1.1% | $12K 0.1% |
| Net Income | -$54.0M -59.7% | -$56.4M -67.3% | -$60.8M -88.6% | -$58.9M -109.8% | -$48.7M -100.5% | -$32.2M -98.5% | -$20.7M -63.5% | -$18.5M -92.4% |
| Per Share | ||||||||
| EPS (Basic) | $-1.33 | $-1.44 | $-1.60 | $-1.59 | $-1.35 | $-3.16 | — | — |
| EPS (Diluted) | $-1.33 | $-1.44 | $-1.60 | $-1.59 | $-1.35 | $-3.16 | — | — |
| Weighted Avg Shares (Basic) | 40.7M | 39.1M | 38.0M | 37.1M | 36.1M | 10.2M | — | — |
| Weighted Avg Shares (Diluted) | 40.7M | 39.1M | 38.0M | 37.1M | 36.1M | 10.2M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$33M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 8 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -59%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 8 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $70M covers all $19M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2021-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~8.5% on $37M of debt.
Cash of $70M fully covers short-term debt of $106000.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-18
Nothing notable to watch.
Where each multiple sits in its own 6-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 6-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 38.6 | 31.2 | 35.2 | 26.4 | 25.7 | 26.1 | 26.0 | 25.8 |
| Gross Profit | 61.4 | 68.8 | 64.8 | 73.6 | 74.3 | 73.9 | 74.0 | 74.2 |
| R&D | 34.9 | 18.6 | 22.8 | 27.0 | 28.7 | 26.3 | 21.0 | 21.5 |
| SG&A | 101.7 | 104.9 | 140.8 | 144.3 | 154.9 | 137.8 | 121.9 | 111.9 |
| Operating Income | -75.2 | -54.7 | -98.8 | -97.7 | -109.3 | -90.2 | -68.9 | -59.3 |
| Income Tax | 0.1 | 1.1 | 0.7 | 0.7 | 0.7 | 0.8 | 0.6 | 0.7 |
| Net Income | -92.4 | -63.5 | -98.5 | -100.5 | -109.8 | -88.6 | -67.3 | -59.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on LUNG: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| LUNG | $86M | — | — | 0.9× | 8.0% | 74.2% | -59.7% | -99.8% | -59.2% | -0.7× | 112 |
Peers = companies sharing LUNG's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.